Key result
Unadjusted glucose cutoffs for whole blood meters may inflate diabetes prevalence by ~2-fold.
Answers are grounded in this paper and cite their sources.
The recent update of the International Diabetes Federation (IDF) statistics on the global prevalence of diabetes suggests that, in 2015, 415 million people had diabetes worldwide, projecting that in 2040 this number will increase to 642 million.1 The IDF strategy bringing together the many different sources used in this analysis includes country-level data sources from peer-reviewed studies, national health statistics reports, commissioned studies on diabetes prevalence, and unpublished data, ranking study quality by study type, design, representativeness, diagnostic criteria, and sample size; studies with glucose tolerance testing (GTT) were used preferentially, but with both whole blood and capillary glucose appearing to have been used in assessment of glycemia.2 The IDF leadership recognizes the limitations of the approaches used, but assert that their estimate of “frequency and prevalence of diabetes is solid”.3 We should note that the precise definition of whether a given individual has diabetes is, in itself, to some extent illusory, given the intra-individual fluctuations in glucose levels over time. O'Sullivan and Mahan, whose pioneering studies of the use of the GTT in determining whether a women has gestational diabetes were tremendously influential in defining the condition, observed in a study of annual repeat GTT in non-pregnant women that there is “considerable individual fluctuation in repetitive testing”, with “the variation within a subject on repeated testing…greater than the differences between individual subjects”.4 We have questioned efforts to use HbA1c as a non-glucose measure to define diabetes, arguing that a variety of physiologic parameters other than glucose levels per se appear to contribute importantly to higher and lower hemoglobin glycation with consequent over- or underdiagnosis of diabetes.5, 6 The measurement of blood glucose, then, appears to be crucial, as long as we recognize its variability in individuals, as well as its role in population studies to understand diabetes prevalence. In the present issue of the Journal of Diabetes, Taylor et al.7 bring up what may be an important caveat to the IDF prevalence measures: in Fiji, Samoa, and Tonga, point-of-care glucose meters used in glucose testing measured glucose in whole blood and reported the concentration in whole blood in 2002–04, whereas in similar surveys in 2011–13 the meters reported glucose concentrations as equivalent to that in plasma. Although fasting whole blood glucose concentrations are approximately 0.5 mmol/L lower than capillary glucose, with the difference increasing to nearly 1.5 mmol/L after a glucose load,8 Taylor et al. note that the same glucose cut-off points were applied for diagnosis of diabetes in the earlier and the more recent surveys, leading to the potential that type 2 diabetes prevalences are “erroneously inflated to approximately double the actual [type 2 diabetes] prevalence had the correct glucose cut-off point been applied”.7 Certainly, these questions are appropriate, and a review of the IDF figures would be welcome. At the same time, we must recognize the tremendous difficulty inherent in combining statistics from a wide variety of sources and, equally, must underscore the importance of the efforts of the IDF and other groups in gaining perspective on the diabetes epidemic, with its growing magnitude and ominous implications for global health.9 最近国际糖尿病联盟(International Diabetes Federation,IDF)对全球糖尿病患病率做了一个最新统计,认为在2015年全世界有4.15亿的人患糖尿病,预计到了2040年这个数字将要增加到6.42亿1。在这项分析中IDF的策略是将许多不同来源的数据集合在一起进行统计,这些国家级的数据源包括来自同行回顾研究、各国卫生统计报告、糖尿病患病率委托研究以及一些未公开的数据,研究质量按照研究类型、设计、代表性、诊断标准以及样本量来分级;优先使用那些采用葡萄糖耐量试验(glucose tolerance testing,GTT)的研究,但是在评估血糖的时候似乎也采用了全血血糖与毛细血管血糖2。IDF领导层也承认所使用的方法具有局限性,但是却声称他们估计的“糖尿病发病率与患病率是可靠的”3。 我们应该注意到的是,要精确地判定一个给定的个体是否具有糖尿病本身在某种程度上就是不可靠的,因为给定个体的血糖水平会随着时间不断地自行波动。在O’Sullivan与Mahan的首创研究中,他们就使用了GTT来确定一名妇女是否具有妊娠糖尿病,结果发现会受到判定标准的极大影响,而在一项非妊娠妇女每年重复进行GTT试验的研究中也观察到了“重复测试中具有相当大的个体波动”,并且“一名受试者在重复测试中就会有差异…这比各个受试者之间的差异大得多”4。我们曾经质疑过那些使用HbA1c而不是通过测量血糖来确定糖尿病的研究,也争论过那些采用多种生理学指标而不是血糖水平本身来确定糖尿病的研究,重要的是似乎更高或者更低的糖化血红蛋白可导致糖尿病过度诊断或漏诊5,6。那么,测量血糖的方法看起来似乎就具有决定性的意义,只要我们能够认识到它在个体中的变异性,以及它在人群研究中的角色,那么我们就能够了解糖尿病的患病率。 在当前这期杂志中,Taylor等7提出了有什么因素可能对IDF患病率测量结果的正确性产生重大的影响:2002-2004年在斐济、萨摩亚以及汤加人中,检测血糖时使用现场及时检验血糖仪来测量全血血糖,报告的却是全血血糖浓度,然而2011-2013年在相似的调查中却将血糖仪报告的血糖浓度等同于血浆血糖。虽然空腹全血血糖浓度大约要比毛细血管血糖浓度低0.5 mmol/L左右,经过葡萄糖负荷之后这种差异增加到了近1.5 mmol/L8,Taylor等发现在更早期或者最近的调查中都应用了相同的血糖截止值来作为糖尿病的诊断标准,这有可能导致2型糖尿病的患病率“虽然使用了正确的血糖截止值但是[2型糖尿病]
No takes yet. Share an insight, caveat, or question.
Zachary T. Bloomgarden (2016) conducted an editorial in Diabetes. Point-of-care glucose meters (whole blood vs plasma equivalence) was evaluated. Using identical glucose cutoff points for whole blood and plasma-equivalent point-of-care meters may erroneously inflate type 2 diabetes prevalence estimates by approximately twofold.
Synapse has enriched 10 related papers. Consider them for comparative context: